Liposome Encapsulated Insulin- a viable option for an intranasal insulin delivery system

Type 2 diabetes mellitus is a widespread condition marked by high blood sugar due to insulin resistance or inadequate insulin production. Traditional insulin therapy through injections is effective but often causes discomfort, fear, and poor compliance. This study introduces a non-invasive nasal delivery system using liposome-encapsulated insulin to overcome these challenges. A custom microfluidic chip was designed to produce uniform, stable insulin-loaded liposomes. Biocompatibility and angiogenic effects were evaluated using the CAM assay on chicken embryos, which showed healthy vascular development without adverse effects. Further in vivo testing on the embryonic model confirmed a significant drop in blood glucose levels after administration. This approach offers a promising, pain-free alternative to injectable insulin, with the potential to improve patient adherence and therapeutic outcomes in managing Type 2 diabetes.